Commun Biol: New findings make leukemia treatment more effective!

July 25, 2020 /PRNewswire/ -- In the latest issue of Communications Biology, Professor Jindrich Cinatl from the Institute of Medical Virology at Goethe University and Professor Martin Michaelis from the School of Biological Sciences at the University of Kent report on their research on different cell lines by Nairabin. Professor
Cinatl explained: "Narrabeen is a precursor to a drug, a precursor drug that only works when it binds to three phosphate-based cells in leukemia cells.
in studies of various cell lines and leukemia cells in all patients, we have shown that SAMHD1 enzymes can break down phosphoric acid, rendering the drug ineffective.
"Because B-ALL cells contain more SAMHD1 than T-ALL cells, nairabin is less effective at B-ALL cells."
Picture Source: These results could improve future TREATMENT of ALL.
in rare cases, B-ALL cells contain very little SAMHD1, so treatment with nairabin is possible.
, on the contrary, there are also a number of rare cases of SAMHD1 in T-ALL.
in this case, the original effective nairabin would not be the right drug. Professor
Michaelis said: "As a result, SAMHD1 is a biomarker that allows us to better use Nairabin therapy to suit the individual circumstances of all patients.
", Tamara Rothenburger's doctoral thesis was funded by the Hilfe fur krebskranke Kinder Frankfurt e. V.
was pleased when she looked back at her research. "I hope that many children with leukemia will benefit from these results, "
.
" the study was also supported by the Frankfurt Erasassociation. The other members of the
team are from Ludwig Maximilian-Munich University and University College London.
() References: php Rothenburger, T., McLaughlin, K., Herold, T. et. SAMHD1 is a regulator key of the lineage-specific of the acute lymphoblastic leukaemias to nelarabine. Commun Biol 3, 324 (2020). https://doi.org/10.1038/s42003-020-1052-8.